AC Immune to Report Progress of Early-Stage Pipeline at AD/PD[TM] Congress
The four oral presentations by
Prof.
Scientific updates at the
Alpha-synuclein PET imaging agent
Identification and characterization of selective and high affinity small molecules for positron emission tomography (PET) imaging of pathological alpha-synuclein
Date:
Location: Auditorium III+IV
Presenter: Oral presentation by F. Capotosti
Determination of the optimal scanning time for the assessment of Tau deposition in Alzheimer’s disease using PI-2620 PET
Date:
Location: Auditorium III+IV
Presenter: Oral presentation by A. Stephens
Compounds targeting Tau aggregation
Small molecules targeting Tau propagation demonstrate efficacy in an aggressive tauopathy mouse model
Date:
Location: Auditorium II
Presenter: Oral presentation by S. Poli
Discovery and development of diagnostics and therapeutics for TDP-43 proteinopathies
Date:
Location: Auditorium II
Presenter: Oral presentation by T. Afroz
About
For further information, please contact:
US Investors Lisa Sher AC Immune Investor Relations Phone: +1 970 987 2654 E-mail: lisa.sher@acimmune.com |
US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 E-mail: kgallagher@lavoiehealthscience.com |
European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 E-mail: chris@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the